HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ICCVAM convenes international panel

This article was originally published in The Rose Sheet

Executive Summary

Interagency Coordinating Committee on the Validation of Alternative Methods placed three nonradioactive modified versions and new applications for the murine local lymph node assay (LLNA) before an independent scientific peer review panel April 28-29 in Bethesda, Md. Panel was made up of 15 experts from six countries, consistent with spirit of a memorandum of cooperation between U.S., EU, Canada and Japan, signed immediately beforehand, aimed at speeding the global adoption of non-animal testing methods through each country's increased involvement in the process by which tests are evaluated and recommended to regulators (1"The Rose Sheet" May 4, 2009, p. 6). Panelists concluded that available data supports use of the LLNA:DA and LLNA:BrdU-ELISA to identify substances as potential skin sensitizers, with certain limitations, while deferring a formal recommendation for a third version of the LLNA (LLNA:BrdU-FC) until an independent audit of supporting data has been conducted. Panel's full report from the meeting will be published in early June; in the meantime, the NTP Interagency Center for the Evaluation of Alternative Toxicological Methods offers a detailed summary online
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

RS016161

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel